How much is Pragma Bio worth in 2026?

Pragma Bio has a current valuation of N/A based on their Early Stage VC (Series A1) round and secondary market data.

How much funding has Pragma Bio raised?

Pragma Bio has raised N/A in total funding across 2 funding rounds.

Pragma Bio

Drug Discovery

Pragma Bio valuation and funding history | Last updated: September 1, 2022 | 2 funding rounds

Current Valuation

N/A

As of September 1, 2022

Total Funding Raised

N/A

Across 2 rounds

Last Round

Early Stage VC (Series A1)

$9.7M

Last Funding

Sep 2022

Funding date

Capital Efficiency

N/A

Valuation / Funding

Funding History & Valuation Timeline

Complete history of all funding rounds and valuation milestones

Date	Round	Amount	Post-Valuation	Growth
September 1, 2022	Early Stage VC (Series A1)	$9.7M	N/A	-
October 18, 2020	Early Stage VC (Series A)	$4.0M	N/A	-

Valuation Analysis

Current Valuation Metrics

Pragma Bio is currently valued at N/A as of September 1, 2022.

Track Pragma Bio Valuation Updates

Get notified when Pragma Bio raises new funding or valuation changes

Explore More Data

Detailed analysis for Pragma Bio

Secondary Market Price

Real-time pricing data and trends

Valuation Tracker

Historical valuation changes

Funding History

Complete funding round timeline

Secondary Price History

Historical transaction data

All Investors

Complete list of all investors

View 5 companies free

Create a free account to unlock Pragma Bio's valuation history, funding rounds, and growth metrics.

No credit card required

What is Pragma Bio Worth in 2026?

Pragma Bio is a leading private company in the Drug Discovery sector. Track Pragma Bio's valuation history, funding timeline, and implied market value from secondary transactions on Premier Alternatives.

How Pragma Bio Valuation is Determined

Private company valuations like Pragma Bio's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including revenue growth, market opportunity, competitive positioning, and investor sentiment.